Epoetin alfa and follow-on generation agents are collectively known as erythropoietin stimulating agents (ESAs), and for many years, these agents have been the standard of care to treat the anemia that occurs in most patients with chronic kidney disease (CKD).
Amgen has dominated the ESA market for well over two decades with blockbuster drugs like Epogen and Aranesp, and the company has successfully fended off competition from other ESA branded products through strategic collaborations in the United States. Further, in 2017, Amgen and Roche/Vifor pharma extended their strategic partnerships with DaVita and Fresenius Medical Center (FMC) dialysis chains, respectively, and these partnerships will continue to be the key factor for maintaining a significant share in the renal anemia market in the coming years. The recent approval of Pfizer’s Retacrit, the first epoetin alfa biosimilar approved in the United States, and Pfizer’s licensing agreement with Vifor pharma prior to approval to commercialize this agent in the U.S. dialysis market highlight the importance of collaborations in the nephrology market.
In this executive briefing we explore key strategic collaborations, including brand defense and biosimilar strategies, and the impact of these partnerships in the renal anemia market.
Download this executive briefing to better understand:
About DRG’S Biosimilars Solutions
Evaluate the risks, opportunities, and strategies underlying biosimilars to uncover opportunities in development or defend your reference brand. Take a close look at this potentially lucrative market as well as the disruptive effects biosimilars could have on the pharmaceutical industry. Assess the current and future market size for biosimilars in four leading therapy areas: oncology, immunology, endocrinology and nephrology. Click here to learn more.